Drug Therapy for Rheumatoid Arthritis in Adults
Summary of Benefits: DMARD Combinations Versus Monotherapies (2 of 2)
In patients whose rheumatoid arthritis failed to respond to methotrexate (MTX), combination therapy with MTX and a biologic disease-modifying anti-rheumatic drug (DMARD) was not more successful than monotherapy with a biologic DMARD. The strength of evidence for this finding is moderate.
In MTX-naïve patients or those not taken MTX recently, combination therapy is superior to monotherapy with a biologic DMARD for functional capacity and quality of life. The strength of evidence for functional capacity is moderate and for quality of life is low.
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic DMARD | withdrawal | methotrexate | functional capacity | quality of life
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.